Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 19
Original Research
Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 3,539 | Dovepress* | 3,348+ | 85 | 3,433 | |
| PubMed Central* | 191 | 90 | 281 | ||
| Totals | 3,539 | 175 | 3,714 | ||
| *Since 5 April 2023 | |||||
View citations on PubMed Central and Google Scholar